Amgen Commits $900M to Expand Ohio Biomanufacturing Facility

Subscribe to our free newsletter today to keep up to date with the latest manufacturing news.

Amgen has announced a major expansion of its biologic medicines manufacturing facility in New Albany, Ohio. The company is investing $900 million to strengthen production capabilities and meet increasing demand for its therapeutics. This expansion brings Amgen’s total commitment to the Central Ohio region to more than $1.4 billion. With plans to add 400 full-time positions, the facility will employ over 750 people once fully operational.

The move supports Amgen’s strategy to expand its US manufacturing footprint while contributing to regional economic growth. The upgraded facility will specialize in product assembly and packaging, speeding the delivery of biologic therapies to patients.

Amgen’s strategic investment in Ohio reflects confidence in regional resources

This investment builds on Amgen’s initial $550 million commitment in 2021, when the company selected New Albany as its newest manufacturing site. The choice was driven by access to a skilled workforce, logistics advantages, and a favorable business environment.

Ohio’s central location offers efficient distribution pathways and access to major markets, while maintaining lower operational costs compared to coastal regions. Amgen emphasized the importance of a technically capable workforce in meeting the demands of advanced manufacturing.

The expansion supports ongoing national efforts to localize pharmaceutical production, improve supply chain resilience, and reduce reliance on overseas operations.

New facility expansion to create hundreds of specialized jobs in Ohio

The New Albany facility will add around 400 full-time jobs across technical operations, quality assurance, engineering, and production management. These positions support the final assembly and packaging of biologic medicines, which require specialized skills and adherence to stringent regulatory standards.

Ohio officials have recognized the expansion as a milestone in the state’s development as a center for high-value manufacturing. The project reflects a broader trend of life sciences companies investing in the Midwest, bringing long-term employment opportunities to the region.

The economic impact is expected to extend beyond direct job creation, boosting demand for local suppliers, construction firms, and supporting industries.

Facility upgrade enhances Amgen’s biologic manufacturing capabilities

Amgen’s New Albany plant is on track to become one of the company’s most advanced global facilities. The expansion will increase capacity for biologic medicines, particularly injectable treatments for cancer, autoimmune disorders, and other chronic diseases.

The new wing will focus on aseptic processing and final packaging, critical steps in maintaining the safety and efficacy of complex therapeutics. The investment will help Amgen meet rising global demand while enhancing speed and reliability in product distribution.

The project also supports Amgen’s goal of achieving carbon neutrality by 2027. The company is implementing energy-efficient systems and sustainable design elements throughout the site.

Sources:

• Plant Services – Amgen Invests $900M in Ohio Facility